Pathology: mNSCLC - L1 - PDL1 negative; mNSCLC - L1 - PDL1 positive;
| mNSCLC - L1 - PDL1 negative | mNSCLC - L1 - PDL1 positive | |||
| CheckMate 227 (NC vs C ; PDL1<1%), 2018 | CheckMate 026 (PDL1>5%), 2016 | CheckMate 026 (PDL1>1%), 2016 | ||
| nivolumab alone | 2 | T1 | T1 | |
| nivolumab plus SoC | 1 | T1 | ||
| pemetrexed plus platin | 0 | T0 | ||
| Standard of Care (SoC) | 0 | T0 | T0 |